Aldosterone receptor antagonism reduces urinary C-reactive protein excretion in angiotensin II-infused, hypertensive rats

Journal of the American Society of Hypertension

Volumn 3, Issue 3, 2009, Pages 184-191

  Ortiz, Rudy M ^a,b   Mamalis, Andrew ^a   Navar, L Gabriel ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Eplerenone; inflammation; mineralocorticoids; spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; ANGIOTENSIN II; C REACTIVE PROTEIN; EPLERENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; HYPERTENSION; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 67349277790     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2009.01.003     Document Type: Article

References (52)

1. Koenig W., Sund M., Fröhlich M., Fischer H.-G., Löwel H., Döring A., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
2. Morrow D., and Ridker P. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 84 (2000) 149-161
3. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in Women. N Engl J Med 342 (2000) 836-843
4. Sesso H., Buring J., Rifai N., Blake G., Gaziano J., and Ridker P. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
5. Anand I.S., Latini R., Florea V.G., Kuskowski M.A., Rector T., Masson S., et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112 (2005) 1428-1434
6. Vongpatanasin W., Thomas G., Schwartz R., Cassis L.A., Osborne-Lawrence S., Hahner L., et al. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation 115 (2007) 1020-1028
7. Kim J.-S., Kang T.S., Kim J.-B., Seo H.-S., Park S., Kim C., et al. Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis 192 (2007) 401-406
8. King D., Egan B., Mainous A., and Geesey M. The effects of extended-release metoprolol succinate on C-reactive protein levels in persons with hypertension. J Clin Hypertens 8 (2006) 257-260
9. Shagdarsuren E., Wellner M., Braesen J.-H., Park J.-K., Fiebeler A., Henke N., et al. Complement activation in angiotensin II-induced organ damage. Circ Res 97 (2005) 716-724
10. Peng N., Liu J.-T., Gao D.-F., Lin R., and Li R. Angiotensin II-induced C-reactive protein generation: inflammatory role of vascular smooth muscle cells in atherosclerosis. Atherosclerosis 193 (2007) 292-298
11. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A.G., Polly M.L., and McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63 (2003) 1791-1800
12. Rocha R., Chander P.N., Khanna K., Zuckerman A., and Stier Jr. C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 (1998) 451-458
13. Rocha R., Martin-Berger C.L., Yang P., Scherrer R., Delyani J., and McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143 (2002) 4828-4836
14. Struthers A.D., and MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61 (2004) 63-70
15. Virdis A., Neves M.F., Amiri F., Viel E., Touyz R.M., and Schiffrin E.L. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40 (2002) 504-510
16. Raio L., Ghezzi F., Mueller M., McDougall J., and Malek A. Evidence of fetal C-reactive protein urinary excretion in early gestation. Obstet Gynecol 101 (2003) 1062-1063
17. Volanakis J.E., Clements W.L., and Schrohenloher R.E. C-reactive protein: purification by affinity chromatography and physicochemical characterization. J Immunol Met 23 (1978) 285-295
18. Volanakis J., and Kaplan M. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med 136 (1971) 612-614
19. Hao L., Kanno Y., Fukushima R., Watanabe Y., Ishida Y., and Suzuki H. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. Am J Nephrol 24 (2004) 54-60
20. Kobayashi N., Hara K., Tojo A., Onozato M.L., Honda T., Yoshida K., et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKC{epsilon}-MAPK-p90RSK, and rho-kinase pathway. Hypertension 45 (2005) 538-544
21. Rocha R., Stier Jr. C.T., Kifor I., Ochoa-Maya M.R., Rennke H.G., Williams G.H., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141 (2000) 3871-3878
22. Sanz-Rosa D., Oubiña M.P., Cediel E., de las Heras N., Aragoncillo P., Balfagón G., et al. Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid Redox Signaling 7 (2005) 1294-1301
23. Suzuki J., Iwai M., Mogi M., Oshita A., Yoshii T., Higaki J., et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26 (2006) 917-921
24. Ortiz R.M., Graciano M.L., Seth D., Awayda M.S., and Navar L.G. Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in Ang II-dependent hypertension. Am J Physiol Renal Physiol 293 (2007) F139-F147
25. Oliveira E.B., Gotschlich E.C., and Liu T.Y. Comparative studies on the binding properties of human and rabbit C-reactive proteins. J Immunol 124 (1980) 1396-1402
26. Oliveira E., Gotschlich E., and Liu T.-Y. Primary structure of human C-reactive protein. Proc Natl Acad Sci 74 (1977) 3148-3151
27. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 38 (2001) 189-197
28. De Ferranti S.D., and Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 16 (2007) 14-21
29. Reinehr T., Stoffel-Wagner B., Roth C.L., and Andler W. High-sensitive C-reactive protein, tumor necrosis factor [alpha], and cardiovascular risk factors before and after weight loss in obese children. Metabolism 54 (2005) 1155-1161
30. Sesso H., Wang L., Buring J., Ridker P., and Gaziano J. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 49 (2007) 304-310
31. Wilson A.M., Ryan M.C., and Boyle A.J. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 106 (2006) 291-297
32. Pasceri V., Chang J., Willerson J.T., and Yeh E.T.H. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103 (2001) 2531-2534
33. Pasceri V., Willerson J.T., and Yeh E.T.H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
34. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low-density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197
35. Li J.-J., and Fang C.-H. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypoth 62 (2004) 499-506
36. Yeh E.T.H., Anderson H.V., Pasceri V., and Willerson J.T. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 104 (2001) 974-975
37. Daugherty A., and Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low-density lipoprotein receptor -/- mice. Ann N Y Acad Sci 892 (1999) 108-118
38. Keidar S., Heinrich R., Kaplan M., Hayek T., and Aviram M. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol 21 (2001) 1464-1469
39. Nobuhiko A., Suganuma E., Babaev V.R., Fogo A., Swift L.L., Linton M.F., et al. Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004) 2143-2148
40. Takaya T., Kawashima S., Shinohara M., Yamashita T., Toh R., Sasaki N., et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 186 (2006) 402-410
41. Godfrey V., Farquharson C.A.J., and MacDonald J.E. Yee K-M, Struthers AD. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol 117 (2007) 282-284
42. Prasad A., Koh K.K., Schenke W.H., Mincemoyer R., Csako G., Fleischer T.A., et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J 142 (2001) 248-253
43. Manabe S., Okura T., Watanabe S., Fukuoka T., and Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 46 (2005) 735-739
44. Davis P.A., Mussap M., Pagnin E., Bertipaglia L., Savica V., Semplicini A., et al. Early markers of inflammation in a high angiotensin II state-results of studies in Bartter's/Gitelman's syndromes. Nephrol Dial Transplant 21 (2006) 1697-1701
45. Agarwal R., Campbell R., and Warnock D. Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin Nephrol 24 (2004) 101-114
46. Kopkan L., Castillo A., Navar L.G., and Majid D.S.A. Enhanced superoxide generation modulates renal function in Ang II-induced hypertensive rats. Am J Physiol Renal Physiol 290 (2006) F80-F86
47. Reckelhoff J.F., and Romero J.C. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol 284 (2003) R893-R912
48. Ferrario C., and Strawn W. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98 (2006) 121-128
49. Suzuki Y., Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., and Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 35 (2003) 881-900
50. Zhao W., Ahokas R.A., Weber K.T., and Sun Y. Ang II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol 291 (2006) H336-H343
51. Armando I., Wang X., Villar V.A.M., Jones J.E., Asico L.D., Escano C., et al. Reactive oxygen species-dependent hypertension in dopamine D2 receptor-deficient mice. Hypertension 49 (2007) 672-678
52. Nishiyama A., Fukui T., Fujisawa Y., Rahman M., Tian R.-X., Kimura S., et al. Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension 37 (2001) 77-83